US · PRGO
Perrigo Company plc
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Dublin 2
- Website
- perrigo.com
Price · as of 2025-12-31
$11.92
Market cap 1.82B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $4.94 | -58.56% |
| Intrinsic Value(DCF) | $4.94 | -58.56% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $72.30 | $66.29 | $181.45 | $21.80 | $105.10 |
| 2012 | $89.24 | $80.01 | $169.91 | $27.30 | $97.69 |
| 2013 | $99.22 | $87.99 | $115.86 | $29.39 | $90.48 |
| 2014 | $117.42 | $83.62 | $19.22 | $45.81 | $39.75 |
| 2015 | $143.94 | $107.20 | $5.92 | $30.35 | $19.23 |
| 2016 | $57.84 | $40.16 | $0.00 | $0.00 | $0.00 |
| 2017 | $69.58 | $58.46 | $0.00 | $8.62 | $1.69 |
| 2018 | $38.55 | $40.93 | $0.00 | $5.23 | $3.73 |
| 2019 | $44.83 | $42.29 | $0.00 | $5.38 | $0.00 |
| 2020 | $35.05 | $31.17 | $0.00 | $0.00 | $0.00 |
| 2021 | $33.29 | $31.34 | $7.13 | $0.00 | $0.00 |
| 2022 | $32.28 | $29.56 | $0.00 | $0.00 | $0.00 |
| 2023 | $28.14 | $30.47 | $0.00 | $0.00 | $0.00 |
| 2024 | $26.85 | $22.85 | $0.00 | $0.00 | $0.00 |
| 2025 | $12.34 | $4.94 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Perrigo Company plc's (PRGO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $4.94
- Current price
- $11.92
- AI upside
- -58.56%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.94
-58.56% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRGO | Perrigo Company plc | $11.92 | 1.82B | -59% | -59% | — | — | -1.20 | 0.58 | 0.40 | -1.52 | -0.17 | 1.94 | 35.14% | 8.07% | -33.51% | -39.29% | 6.99% | -15.68% | 0.01 | 2.11 | 2.76 | 1.13 | 0.62 | 72320.00% | -275.00% | -4068.00% | 8.49% | 0.24 | 2.96% | 9.32% | -11.20% | 217.29% | 3.54 | 8.37 | 0.29 | 0.46 |
| ATEC | Alphatec Holdings, Inc. | $13.62 | 2.02B | +183% | +162% | — | — | -14.10 | 56.10 | 2.65 | -62.48 | — | -15.24 | 69.60% | -10.75% | -18.76% | -630.66% | -16.83% | -18.30% | 17.21 | -3.88 | 2.06 | 1.18 | -11.57 | -1504.00% | 2495.00% | -10201.00% | 0.14% | 0.21 | 0.57% | 0.00% | 0.00% | 0.59% | -30.20 | 893.55 | 3.25 | 0.06 |
| BHC | Bausch Health Companies I… | $5.93 | 2.2B | +958% | +67% | — | +6% | 18.37 | -3.99 | 0.21 | 7.14 | — | -0.13 | 68.33% | 20.07% | 1.51% | -13.10% | 4.28% | 0.45% | -38.35 | 1.37 | 1.47 | 0.88 | 6.42 | -41538.00% | 711.00% | -2040.00% | 45.49% | 0.34 | 5.18% | 0.00% | 0.00% | 34.48% | 10.68 | 22.02 | 2.14 | 0.28 |
| FOLD | Amicus Therapeutics, Inc. | $14.37 | 4.51B | +149% | -39% | — | — | -163.34 | 16.15 | 6.98 | 85.82 | — | 70.82 | 87.32% | 5.44% | -4.27% | -11.58% | 3.24% | -3.13% | 1.76 | 0.75 | 2.84 | 1.72 | 5.00 | -5117.00% | 2005.00% | -17972.00% | 0.67% | 0.14 | 7.01% | 0.00% | 0.00% | 0.00% | 133.89 | 154.71 | 7.28 | 1.20 |
| HCM | HUTCHMED (China) Limited | $14.33 | 2.59B | +159% | -38% | -61% | — | 74.95 | 3.72 | 4.49 | 147.56 | — | 3.74 | 44.64% | -6.94% | 5.99% | 5.06% | 131.28% | 2.95% | 0.12 | -15.22 | 2.83 | 2.67 | -4.55 | -6333.00% | -2480.00% | -10934.00% | -0.62% | 0.00 | 62.24% | 0.00% | 0.00% | 1.28% | -47.63 | -119.38 | 3.30 | 3.49 |
| HTFL | Heartflow, Inc. Common St… | $23.16 | 1.97B | — | — | — | — | — | — | — | — | — | — | 75.07% | -48.66% | -76.65% | 11.78% | 8.22% | -63.49% | -0.19 | -2.69 | 2.45 | 2.33 | -1.67 | -2320.00% | 4432.00% | -1112.00% | — | -2.05 | 9.85% | — | 0.00% | — | — | — | — | — |
| LIVN | LivaNova PLC | $70.60 | 3.86B | +8% | -48% | — | — | -15.79 | 3.19 | 2.76 | -28.32 | — | 21.61 | 67.71% | 14.36% | -17.47% | -19.24% | 15.30% | -9.49% | 0.39 | 4.04 | 1.36 | 1.05 | 1.25 | -48362.00% | 1074.00% | 2742.00% | 4.52% | 0.31 | 13.29% | 0.00% | 0.00% | 10.83% | 18.39 | 21.17 | 2.64 | 2.55 |
| SGRY | Surgery Partners, Inc. | $15.50 | 2B | +214% | -38% | — | — | 242.66 | 1.69 | 0.97 | 12.90 | 18.60 | -0.91 | 23.94% | 11.20% | -5.40% | 0.66% | 2.77% | 0.17% | 2.07 | 1.73 | 1.79 | 1.36 | 6.85 | 130444.00% | 1352.00% | 229.00% | 6.91% | 0.48 | 4.16% | 0.00% | 0.00% | 0.00% | 18.54 | 30.84 | 2.08 | 0.91 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
| SUPN | Supernus Pharmaceuticals,… | $54.73 | 3.14B | +101% | -41% | -57% | -59% | 23.92 | 1.71 | 2.67 | 7.56 | 0.44 | 4.45 | 88.23% | 12.34% | 11.16% | 7.55% | 9.31% | 5.58% | 0.03 | — | 2.35 | 2.04 | -0.20 | 546962.00% | 894.00% | 5491.00% | 9.69% | 0.59 | 25.85% | 0.00% | 0.00% | 0.09% | 16.50 | 7.87 | 2.04 | 4.79 |
| TARS | Tarsus Pharmaceuticals, I… | $75.52 | 3.21B | +33% | +191,318% | -100% | — | -48.71 | 9.42 | 7.17 | -54.31 | — | 9.63 | 93.20% | -15.72% | -14.72% | -23.39% | -558.70% | -14.14% | 0.27 | -7.94 | 3.85 | 3.72 | 1.68 | -4821.00% | 14671.00% | -7363.00% | -0.69% | -0.09 | -175.63% | 0.00% | 0.00% | 2.09% | -41.03 | -130.51 | 6.45 | 9.02 |
About Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- CEO
- Patrick Lockwood-Taylor
- Employees
- 8.38K
- Beta
- 0.40
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.94 ÷ $11.92) − 1 = -58.56% (DCF, example).